![COVID vaccinations: questions and answers about the rollout in North Yorkshire - NHS North Yorkshire CCG COVID vaccinations: questions and answers about the rollout in North Yorkshire - NHS North Yorkshire CCG](https://northyorkshireccg.nhs.uk/wp-content/uploads/2022/01/Covid-Vaccine-Eligibility-v4-scaled.jpg)
COVID vaccinations: questions and answers about the rollout in North Yorkshire - NHS North Yorkshire CCG
![8 in 10 UK citizens willing to donate their COVID-19 booster dose if not needed | Imperial News | Imperial College London 8 in 10 UK citizens willing to donate their COVID-19 booster dose if not needed | Imperial News | Imperial College London](https://www.imperial.ac.uk/ImageCropToolT4/imageTool/uploaded-images/newseventsimage_1625496848614_mainnews2012_x1.jpg)
8 in 10 UK citizens willing to donate their COVID-19 booster dose if not needed | Imperial News | Imperial College London
![80% of patients admitted to Intensive Care Units in north east London in December not fully vaccinated - NHS North East London 80% of patients admitted to Intensive Care Units in north east London in December not fully vaccinated - NHS North East London](http://northeastlondon.icb.nhs.uk/wp-content/uploads/2022/01/NHS-covid-hospital-stats-0122-ICU.jpg)
80% of patients admitted to Intensive Care Units in north east London in December not fully vaccinated - NHS North East London
![Severe COVID-19 outcomes after full vaccination of primary schedule and initial boosters | The University of Edinburgh Severe COVID-19 outcomes after full vaccination of primary schedule and initial boosters | The University of Edinburgh](https://www.ed.ac.uk/sites/default/files/styles/landscape_breakpoints_theme_uoe_mobile_1x/public/thumbnails/image/final_v0.3_vbp_booster_vbs_infographic_3.png?itok=dgJ-Kjqg)
Severe COVID-19 outcomes after full vaccination of primary schedule and initial boosters | The University of Edinburgh
![Safety and immunogenicity of seven COVID-19 vaccines as a third dose ( booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial - Safety and immunogenicity of seven COVID-19 vaccines as a third dose ( booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial -](https://www.thelancet.com/cms/attachment/966d70c5-8395-4ea2-9a35-94dc18f2f550/gr1.gif)